Endovascular stroke treatment does not preclude high thrombolysis rates.
S FedaO NikoubashmanK SchürmannO MatzS C TauberM WiesmannJ B SchulzArno ReichPublished in: European journal of neurology (2018)
Intravenous recombinant tissue plasminogen activator remains the most frequently applied reperfusion therapy in AIS patients presenting within 4.5 h of onset in a tertiary stroke centre. An effective thrombolysis rate of over 80% can be achieved without increased rates of sICH.
Keyphrases
- acute ischemic stroke
- pulmonary embolism
- atrial fibrillation
- end stage renal disease
- newly diagnosed
- cerebral ischemia
- ejection fraction
- acute myocardial infarction
- peritoneal dialysis
- high dose
- stem cells
- low dose
- coronary artery disease
- case report
- subarachnoid hemorrhage
- brain injury
- mesenchymal stem cells
- patient reported